Chai Discovery Stock Price, Valuation & IPO
Private company — Chai Discovery is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$257.99 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 27 October 2026
Last round valuation: $3.8B
Source: C, July 2026, post-money
Total raised: $630M
Data last updated: 27 October 2026
About Chai Discovery
Builds the Chai-1 and Chai-2 foundation models for protein structure prediction, molecular design, and zero-shot antibody design, accelerating drug discovery.
Chai Discovery is a US biotech company founded in March 2024 in San Francisco by alumni of OpenAI, Meta, and Stripe. It builds AI models that design antibody molecules in silico for a given target: months of lab-based screening compress into a few weeks, and only dozens of candidates need validation instead of thousands. The company sells pharma companies access to its platform and trains custom model versions on their internal data. Since January 2026, Eli Lilly, Pfizer, Novartis, argenx, and Bristol Myers Squibb have signed on, with the BMS agreement covering its entire target portfolio. In July 2026 the company raised $400 million in a Series C at a $3.8 billion valuation, bringing total funding to $630 million.
- Sector: Healthcare & Biotech
- Headquarters: San Francisco, California, USA
- Founded: 2024
Key highlights
- Models trained on customer data. Pfizer and Lilly already have model versions trained on their own internal data. This product commands a premium over standard access and is nearly impossible to port to a competitor, which locks customers into Chai for the long term.
- Expansion within existing partners. The Bristol Myers Squibb agreement now covers its entire target portfolio, though the partnership started with individual programs. Each new target from the same customer adds revenue without any customer-acquisition cost.
- Small biotechs via Lilly. Through Lilly's TuneLab, Chai's models are available to more than a hundred early-stage companies. This is a ready-made sales channel into a segment that would be expensive for Chai's own team to reach one company at a time.
- Hard targets and complex molecules. Chai-3 designs molecules that act on multiple targets at once and handles proteins that resisted earlier methods. This opens up programs pharma previously wouldn't touch and raises the value of each contract.
- Compute as the quality driver. The founders treat molecular design as a scaling problem, where model quality improves alongside compute and data. Series C proceeds go primarily toward compute capacity and data, which should drive the next jump in accuracy.
- Pharma experience on the board. The board includes Mikael Dolsten, who led R&D at Pfizer for 15 years and brought 36 drugs to market. His relationships help Chai get faster access to leadership at major pharma companies.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 14 July 2026 | C | $178.05 | $3.8B |
| 15 December 2025 | B | $67.66 | $1.3B |
| 6 August 2025 | A-1 | $33.65 | $550M |
| 9 September 2024 | Seed | $8.51 | $150M |
Latest news
Frequently asked questions
How can I buy Chai Discovery stock before the IPO?
Not on a public exchange — Chai Discovery is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Chai Discovery stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $257.99 per share as of 27 October 2026. Its most recent round implied a post-money valuation of $3.8B (July 2026).
What is Chai Discovery's valuation (net worth)?
Chai Discovery's most recent funding round valued the company at $3.8B post-money (July 2026) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Chai Discovery IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Chai Discovery publicly traded?
No. Chai Discovery is a private company and its shares are not listed on any public exchange.
Does Chai Discovery have a stock symbol?
No. Chai Discovery has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Neuralink — Healthcare & Biotech
- Benchling — Healthcare & Biotech
- Altos Labs — Healthcare & Biotech
- Ayar Labs — Semiconductors
- The Bot Company — Robotics
- Chainguard — Cybersecurity
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.